Monogram Orthopaedics (NASDAQ:MGRM – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03, Zacks reports.
Monogram Orthopaedics Price Performance
NASDAQ MGRM opened at $2.32 on Thursday. Monogram Orthopaedics has a 12 month low of $1.53 and a 12 month high of $4.90. The company has a market capitalization of $79.60 million, a price-to-earnings ratio of -4.94 and a beta of 1.66. The company’s fifty day moving average price is $2.54 and its two-hundred day moving average price is $2.50.
Wall Street Analyst Weigh In
A number of research firms recently weighed in on MGRM. Roth Mkm began coverage on shares of Monogram Orthopaedics in a report on Monday, December 9th. They set a “buy” rating and a $4.00 price target for the company. Roth Capital raised shares of Monogram Orthopaedics to a “strong-buy” rating in a report on Monday, December 9th.
About Monogram Orthopaedics
Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.
Featured Stories
- Five stocks we like better than Monogram Orthopaedics
- Canada Bond Market Holiday: How to Invest and Trade
- Nu Holdings: Is Brazil’s Fintech Leader a Buy at This Discount?
- How to Buy Cheap Stocks Step by Step
- 3 Magnificent 7 Stocks Trading Near 50-Day Lows—Time to Buy?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 3 Stocks With Ironclad Balance Sheets for Long-Term Stability
Receive News & Ratings for Monogram Orthopaedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monogram Orthopaedics and related companies with MarketBeat.com's FREE daily email newsletter.